van der Sar, Iris G.
Wijsenbeek, Marlies S.
Braunstahl, Gert-Jan
Loekabino, Jason O.
Dingemans, Anne-Marie C.
In ‘t Veen, Johannes C. C. M.
Moor, Catharina C.
Article History
Received: 25 August 2023
Accepted: 22 October 2023
First Online: 6 November 2023
Declarations
:
: The study was conducted in accordance with the amended Declaration of Helsinki. All participants signed informed consent before participating. The medical ethics committee of Erasmus Medical Center approved the study protocol (MEC-2019-0230).
: Not applicable.
: IS reports an unrestricted grant from Boehringer Ingelheim, outside the submitted work and paid to her institution. MW reports received consultancy or speaker fees from Astra-Zeneca, Bristol Myers Squibb, CSL Behring, Galapagos, Galecto, Horizon Therapeutics, Kinevant Sciences, Molecure, NeRRe Therapeutics, Novartis, PureTech Health, Thyron and Vicore paid to her institution; grants from Boehringer-Ingelheim, Astra-Zeneca/Daiichi-Sankyo and Hoffmann-La Roche; all outside the submitted work. GB reports grants and personal fees from Sanofi, GSK, AstraZeneca and ALK Abello; grants from Sanofi and AstraZeneca; all outside the submitted work. JL has nothing to disclose. AD reports grants from Amgen, Dutch Cancer Society and HANART; consulting fees from AMGEN, Bayer, Boehringer Ingelheim, Sanofy, Roche, Jansen and Astra Zeneca; speaker fees from Janssen, Pfizer, AstraZeneca, Lilly and Takeda; all outside the submitted work and paid to her institution. JV reports unrestricted grants from Chiesi, AstraZeneca and Teva; personal fees from GSK, Sanofi, Chiesi and AstraZeneca; all outside the submitted work. CM reports an unrestricted research grant from Boehringer-Ingelheim, Astra-Zeneca and Daiichi-Sankyio, paid to her institution.